A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 9, Issue 11, 2003, Pages 4108-4115

  Herbst, Roy S ^a   Hammond, Lisa A ^b   Carbone, David P ^c   Tran, Hai T ^a   Holroyd, Kenneth J ^d   Desai, Avinash ^d   Williams, Jon I ^d   Bekele, B Nebiyou ^a   Hait, Howard ^d   Allgood, Victoria ^a   Solomon, Stephen ^d   Schiller, Joan H ^e,f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CTRC Institute for Drug Development   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d Genaera Corporation   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; MSI 1256F; PACLITAXEL; SQUALAMINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; HEMOPTYSIS; HUMAN; HYPOKALEMIA; HYPONATREMIA; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; NEURITIS; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHOLESTANOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LACTATES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PATIENT SELECTION; PLEURAL EFFUSION; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0141566695     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Williams, J. I. Squalamine - a new angiostatic steroid. In: B. Teicher (ed.), Antiangiogenic Agents, pp. 153-174. Plymouth, MA: Humana Press, 1998.
2. Sills, A. K., Jr., Williams, J. I., Tyler, B. M., Epstein, D. S., Sipos, E. P., Davis, J. D., McLane, M. P., Pitchford, S., Cheshire, K., Gannon, F. H., Kinney, W. A., Chao, T. L., Donowitz, M., Laterra, J., Zasloff, M., and Brem, H. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res., 58: 2784-2792, 1998.
3. Moore, K. S., Wehrli, S., Heinrich, R., Rogers, M., Forrest, J. N. J., McCrimmon, D., and Zasloff, M. Squalamine: an aminosterol antibiotic from the shark. Proc. Natl. Acad. Sci. USA, 90: 1354-1358, 1993.
4. Akhter, S., Nath, S. K., Tse, C. M., Williams, J., Zasloff, M., and Donowitz, M. Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na+/H+ exchanger isoform NHE3. Am. J. Physiol., 276: C136-C144, 1999.
5. Teicher, B. A., Williams, J. I., Takeuchi, H., Ara, G., Herbst, R. S., and Buxton, D. Potential of the aminosterol, squalamine, in combination therapy in the rat 13762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res, 18: 2567-2574, 1998.
6. Schiller, J. H., and Bittner, G. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization. Clin. Cancer Res., 5: 4287-4294, 1999.
7. Williams, J. I., Mangold, G., Zasloff, M., and Von Hoff, D. D. Evaluation of the angiostatic steroid squalamine as adjunctive chemotherapy for the MX-1 breast cancer in a mouse model. Breast Cancer Res. Treat., 46: 723-733, 1997.
8. Pietras, R. D., Li, D., and Williams, J. I. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with and without overexpression of HER-2/neu oncogene. Proc AACR-NCI-EORTC International Conference, November 16-19, 1999, Washington, DC. Clin. Cancer Res., 5 (Suppl.): 3809, 1999.
9. 3 expression by squalamine obliterates advanced human prostate cancer (HPC): synergism with VEGF. Proc. Am. Assoc. Cancer Res., 40: 409, 1999.
10. Williams, J. I., Weitman, S., Gonzalez, C. M., Jundt, C. H., Marty, J., Stringer, S. D., Holroyd, K. J., Mclane, M. P., Chen, Q., Zasloff, M., and Von Hoff, D. D. Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin. Cancer Res., 7: 724-733, 2001.
11. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., and Johnson, D. H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med., 346: 92-98, 2002.
12. Carney, D. N. Lung cancer-time to move on from chemotherapy. N. Engl. J. Med., 346: 126-128, 2002.
13. Sheperd, F. A. Chemotherapy for non-small cell lung cancer: Have we reached a new plateau? Semin. Oncol., 26 (Suppl. 4): 3-11, 1999.
14. Herbst, R. S., Mullani, N. A., Davis, D. W., Hess, K. R., McConkey, D. J., Charnsangavej, C., O'Reilly, M. S., Kim, H-W., Baker, C., Roach, J., Ellis, L. M., Rashid, A., Pluda, J., Bucana, C., Madden, T. L., Tran, H. T., and Abbruzzese, J. L. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol., 20: 3804-3814, 2002.
15. Herbst, R. S., Madden, T. L., Tran, H. T., Blumenschein, G. R., Jr., Meyers, C. A., Seabrooke, L. F., Khuri, F. R., Puduvalli, V. K., Allgood, V., Fritsche, H. A., Jr., Hinton, L., Newman, R. A., Crane, E. A., Fossella, F. V., Dordal, M., Goodin, T., and Hong, W. K. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small cell lung cancer. J. Clin. Oncol., 20: 4440-4447, 2002.
16. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
17. Lilenbaum, R. C., Herndon, J., List, M., Desch, C., Watson, D., Holland, J., Weeks, J. C., and Green, M. R. Single agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost effectiveness. Proc. Am. Soc. Clin. Oncol., 21: la, 2002.
18. Sandler, A. B., Nemunaitis, J., Denham, C., Von Pawel, J., Connier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M. C., Gregor, A., Nguyen, B., Niyikiza, C., and Einhorn, L. H. Phase III trial of gemcitabine plus cisplatin versus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol., 18: 122-130, 2000.
19. Li, D., Williams, J. I., and Pietras, R. J. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER2 gene overexpression. Oncogene, 21: 2805-2814, 2002.
20. Bhargava, P., Marshall, J. L., Dahut, W., Rizvi, N., Trocky, N., Williams, J. I., Hait, H., Song, S., Holroyd, K., and Hawkins, M. A Phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent in patients with advanced cancers. Clin. Cancer Res., 7: 3912-3919, 2001.
21. Johnson, D. H., DeVore, R., Kabbinavar, F., Herbst, R., Holmgren, E., and Novotny, W. Carboplatin + paclitaxel + rhumab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc. Am. Assoc. Clin. Oncol., 20: 315a, 2001.
22. Schiller, J. H., and Bittner, G. N. Antitumor effects of squalamine, a novel antiangiogenic agent, plus cisplatin in human lung cancer xenografts. Proc. Am. Assoc. Cancer Res., 39: 45, 1998.
23. Schiller, J. H., and Bittner, G. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization. Clin. Cancer Res., 5: 4287-4294, 1999.
24. Folkman, J. New perspectives in clinical oncology from angiogenesis research. Eur. J. Cancer, 32: 2534-2539, 1996.